Satellite Symposia

¹⁸F-PSMA-1007 PSMA PET-CT in routine clinical use – experiences and expectations

Sunday, October 20, 2024 (13:15 – 14:45)

Hall X1-X4

Chair: F.Giesel

Speaker (presentation time 12-15 min):

Points to be covered:

• Imaging with PSMA-1007 – prime time? / F. Giesel
• Pitfalls and Standardized Reporting/ W. Fendler
• Why is PSMA-imaging a game changer for the diagnosis and treatment of PCa? The urologists perspective/ T. Maurer
• 1007 PSMA PET-CT imaging current and future aspects / K.Rahbar
• Case discussion
• Conclusions and outlook /F. Giesel

Content/Abstracts/Speakers will be mentioned here as soon as confirmed.

Unlocking Healthcare System Readiness: Strategies for Advancing
Theranostics in Oncology

AGENDA – OVERVIEW

This symposium is organized and funded by Novartis in the context of EANM 2024, in Germany. This scientific program and/or material was developed for use outside of the US, intended solely for non-US physicians and pharmacists, and is to be used in accordance with local laws and regulations. The aim of this medical symposium is scientific, educational and not promotional. This scientific information may include data/ information on investigational uses of
compounds/drugs that have not yet been approved by regulatory authorities. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country.

SIRT in action: Cutting-edge TheraSphere dosimetry for hepatic malignancies

Speakers: Dr. Arthur J.A.T. Braat (Moderator), Dr. Marco Maccauro, Dr. Cigdem Soydal

Presentations:

• Maximizing HCC treatments with TheraSphere: activity matters, not just dose  (20 min)Dr. Marco Maccauro, Director Nuclear Medicine Department, Fondazione IRCCS “Istituto Nazionale dei Tumori” Milano, Italy

• Understand the importance of radiation per microsphere activity-based dosimetry in hepatocellular carcinoma (HCC) radioembolization.
• Discuss tumor coverage-activity relationship and particle loads impact.

• Optimizing treatment planning for NETs and mCRC: Dosimetry Recommendations (20 min)
  Dr. Arthur J.A.T. Braat, Nuclear Medicine Physician, M.D. Ph.D., Associate Professor, University Medical Center Utrecht, The Netherlands​

• Explore dosimetry guidelines specific to neuroendocrine tumors (NETs) and metastatic colorectal cancer (mCRC) treated with radioembolization.
• Discuss personalized dosimetry planning approaches to enhance treatment outcomes in NETs and mCRC patients

• Enhancing mCRC Radioembolization Treatments: Dosimetry insights with Simplicit90Y Software and Multicenter experience (20 min)
  Dr. Cigdem Soydal, Assistant Professor Nuclear Medicine, Ankara University Hospital, Turkey​

• Gain insights into the role of Simplicit90Y software in optimizing dosimetry for mCRC radioembolization.
• Discuss the impact of TheraSphere Y-90 Therapy for improved mCRC patient outcomes.

Does size matter in targeted radionuclide therapies ?

Chair: Prof. Viktor Grunwald

• Introduction
  Prof. Viktor Grunwald, University Hospital Essen, Essen, Germany
• Why size matters: the relative benefits of antibodies vs. small molecules in oncology
  Prof. Arturo Chiti, IRCCS San Raffaele Hospital, Milan, Italy
• When small is the best option: the role of small molecules in neuro-oncology
  Prof. Nathalie Albert, Ludwig-Maximilian’s-University of Munich, Munich, Germany
• Where big is winning: the power of antibodies in onco-haematology
  Prof. Stefano Fanti, University of Bologna, Bologna, Italy
• How size will shape the future: the choice between antibodies and small molecules in uro-oncology
  Prof. Karolien Goffin, University Hospital Leuven, Leuven, Belgium
• Concluding remarks
  Prof. Viktor Grunwald

Patient-Centric Innovations: The Impact of Rhenium-SCT on Non-Melanoma Skin Cancer

Why is PSMA PET here to stay?

Our speakers who are leaders in the field of prostate cancer will share their clinical experience:

• Prof. Dr. Jochen Christoph Walz, Urologist
  Department of Urology
  Institut Paoli-Calmettes Cancer Centre
  Marseille, France
• Dr. Harun Ilhan, Nuclear Medicine Physician
  Department of nuclear medicine
  Die Radiologie
  München, Germany
• Dr. Gary Cook, Nuclear Medicine Physician
  Department of Cancer Imaging
  King’s College London
  London, UK

Symposium summary:

Nowadays, prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is taking a central role in the daily management of patients with prostate cancer.

Our speakers will focus on the role PSMA PET radiopharmaceuticals play in their practice – from the perspective of a urologist and nuclear medicine physician.

Revolutionizing Healthcare: Leveraging New Clinical Potential with PET Technology

Embark on a journey to explore new clinical frontiers with PET technology at this year’s symposium, proudly sponsored by United Imaging. We will delve into pioneering advancements in next-generation molecular imaging technologies, including the Total-body PET/CT uEXPLORER, the 148-cm whole-body PET/CT uMI Panorama GS and HD TOF PET/MR uPMR 790. Join us at the 2024 EANM Annual Conference to discover the diverse and exciting future of molecular imaging.

Speakers:

1. Clemens Mingels – University of California, Davis | UCD · Department of Radiology · Doctor of Medicine
2. Stefano Fanti – Full Professor (sector MED-36, Diagnostic Imaging) at the University of Bologna, Director of Nuclear Medicine Division and of PET Unit at the Policlinico S.Orsola, Director of Specialty School of Nuclear Medicine at University of Bologna.
3. Delphine Chen–  Director of Molecular Imaging and Therapy, Fred Hutch
   Wil B. Nelp, MD Endowed Professorship in Nuclear Medicine; Professor, Department of Radiology, University of Washington School of Medicine

Shaping the future of the nuclear medicine department​

Format: Plenary presentations followed by a panel discussion​
Moderator: Prof K. Herrmann, Essen University Hospital​, Germany

Advancing cardiac PET accessibility: the role of novel tracers
Prof. Francois Rouzet, Head of Nuclear Medicine Department, Bichat Hospital, France
Dr. Arthur Braat, M.D. Ph.D. University Medical Center Utrecht, The Netherlands

Leveraging new technology to elevate nuclear medicine imaging
Prof. Louise Emmett, St Vincent’s Hospital, Sydney, Australia
Prof. Jan Abrahamsen, Regional Hospital Viborg, Denmark

Additional panelists:
Prof. Irene Burger, Kantonsspital Baden, Switzerland
Prof. Mike Sathekge, NuMeRI, South Africa
Prof. Andrei Iagaru, USA

Panel Discussion about the future of Molecular Imaging

Exploring Novel Combinations in mCRPC Care: Radioligands and Beyond

​Breaking Barriers in Digital SPECT Imaging

• AI Denoising in SPECT Imaging
  Dr. Laetitia Imbert, CHRU Nancy, France – 15 minutes

• New Theranostics Applications  – Quantitation of Dual peak Lu-177 PSMA Imaging
  Dr. Desiree Deandreis, Institut Gustave Roussy, Grand Paris, France

• Comparison of AC Rb PET to TruCorr AC SPECT MPI
  Prof. Pierre Yves Marie; CHRU Nancy, France

• Cardiac Amyloid Imaging and Quantification on the DSPECT
  Dr. Maria Koutelou, Onassis Cardiac Surgery Center, University of Athens

Alzheimer’s Disease Case Conference: Acquiring New Skills, Visualizing Emerging Strategies for the Era of Amyloid-Targeting Therapies

Optimizing nuclear imaging for enhanced care in ATTR-CM

Meeting Objectives:

• Raise awareness among specialists about the key clinical red flags indicative of cardiac amyloidosis, emphasizing the importance of early recognition, referral and treatment
• Share clinical data and safety outcomes of tafamidis in the treatment of ATTR-CM, highlighting results from clinical trials and real-world applications
• Highlight best-practice guidelines on the use of cardiac scintigraphy in achieving an accurate diagnosis of ATTR-CM
• Share clinical experience on the practical application of cardiac scintigraphy in diagnosing ATTR-CM